Neoadjuvant QL1706 therapy for esophageal cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal squamous cell cancer that has spread to nearby lymph nodes or is locally advanced, but not to distant organs.
- Your doctor plans to do surgery after you finish neoadjuvant therapy.
- You are in good enough health to perform daily activities on your own (ECOG performance status 0 or 1).
- You do not have active autoimmune diseases, serious heart conditions, or uncontrolled bleeding risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (Iparomlimab and Tuvonralimab, combined as QL1706) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced stomach or gastroesophageal junction cancer that can be surgically removed.
This trial tests adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery for a certain type of esophageal cancer. The goal is to see if the combination works better than chemotherapy alone at shrinking the tumor and improving surgery outcomes.
This study tests a new treatment approach for patients with advanced esophageal cancer whose disease progressed or didn't respond to initial chemotherapy and immunotherapy. The goal is to see if this new treatment can help shrink tumors and improve outcomes for patients who cannot have surgery.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and lenvatinib before surgery to treat esophageal squamous cell carcinoma that hasn't spread and can be removed. It aims to see if this approach can improve outcomes for patients with stage II to IVa disease.
This trial tests a new combination of drugs (QL1706 and lenvatinib) for people with advanced esophageal cancer that has stopped responding to standard immunotherapy. The goal is to see if this new treatment can help shrink tumors or slow the cancer's growth.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
Hear when a new Locally Advanced Resectable Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.